Navigation Links
Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Date:12/5/2012

er more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

References

  1. American Cancer Society. Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-breast-cancer-types. Accessed November 2012.
  2. Living Beyond Breast Cancer: Guide to Understanding Triple-Negative Breast Cancer 2nd Edition 2012. Available at http://www.lbbc.org/Understanding-Breast-Cancer/Guides-to-Understanding-Breast-Cancer/Guide-to-Understanding-Triple-Negative-Breast-Cancer. Accessed November 2012.

 

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with brostallicin in particular, including, without limitation, the potential failure of brostallicin to prove safe and effective for the treatment of women with metastatic triple-negative breast cancer, either alone or in combination with cisplatin, as determined by the U.S. Food and Drug Administration and/or the European Medicines Agency; that additional clinical trials of brostallicin may not occur as planned; CTI's ability to continue to raise capital as needed to fund its operations; and competitive factors, technological develo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
4. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
5. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
6. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
7. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
8. Alzheimers Therapeutics Reviewed by NeuroPerspective
9. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/tdw3ss/2015_strategies ) has ... in the UK Flow Cytometry Market" report ... a comprehensive analysis of the UK flow cytometry ... the French flow cytometry practice, as well as ... with significant market impact during the next five ...
(Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
(Date:5/31/2015)... The most heavily attended and popular session at ... Meeting – “The Plenary Session Including the Science of ... immunotherapy experts and members of the Society for Immunotherapy ... of the Department of Immunology at the University of ... received the Science of Oncology Award. The Science of ...
(Date:5/30/2015)... 2015 The Cholangiocarcinoma Foundation (CCF), ... bile duct cancer, announced today the first grant ... , The Foundation has awarded 5 ... country to raise awareness about cholangiocarcinoma and inspire ... that opens new pathways for diagnosis and drug ...
Breaking Biology Technology:Strategies in the UK Flow Cytometry Market 2015 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3SITC Reports on Immunotherapy Insights and Data Featured at ASCO Plenary Session 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... system, described as a breakthrough advancement in breast imaging, ... Drug Administration. , ,The system offers more evidence that ... tools that enable higher quality images for the detection ... GE Healthcare said the Senographe Essential system ...
... we asked William Yasnoff, founder of the eHealthTrust initiative, why ... that today are fractured and limited. , , ... William Yasnoff Yasnoff is a speaker at ... deliver a presentation titled "A New Patient-Centric and Sustainable Approach ...
... Madison, Wis. The Wisconsin Technology Council ... legislature with statewide membership arms, has announced eight additions ... have three-year terms and will join a board that ... business technology community. Electees include four technology organization leaders: ...
Cached Biology Technology:FDA approves advanced digital mammography system 2Interview: Dr. William Yasnoff on health records, part 2 2Interview: Dr. William Yasnoff on health records, part 2 3Interview: Dr. William Yasnoff on health records, part 2 4Interview: Dr. William Yasnoff on health records, part 2 5Interview: Dr. William Yasnoff on health records, part 2 6
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... free. But we'd all agree it's not worthless. So, ... , In 1997, the University of Vermont's Robert Costanza ... per year in a now-famous paper in the journal ... services" has bloomed. This young discipline studies how nature--through ...
... developed the first-ever genomic test to predict which patients ... and which patients can avoid the toxic regimen of ... save thousands of lives each year by recommending chemotherapy ... the test's developers at Duke's Institute for Genome Sciences ...
... therapy extends average life expectancy and decreases recurrences of ... lung cancer, according to researchers at Rhode Island Hospital. ... seven years, the median survival rate at three years ... months when thermal ablation was followed by radiation for ...
Cached Biology News:What's nature worth? New computer models tell all 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
... a fluorescent microscopy-based imaging system that accurately ... automatically calculates cell viability, in a single ... the variability associated with the subjective interpretation ... the EasyCount ViaSure Kit, up to six ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
Biology Products: